Compare Natera Inc. Common Stock (NTRA) vs SharkNinja Inc. Ordinary Shares (SN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs SharkNinja Inc. Ordinary Shares — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while SharkNinja Inc. Ordinary Shares trades at $186 (market cap $26.25B). The key difference: Natera Inc. Common Stock is far larger — about 2.2× SharkNinja Inc. Ordinary Shares's market cap, and SharkNinja Inc. Ordinary Shares is more actively traded (1,135,281 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and SharkNinja Inc. Ordinary Shares for 3 Days on average.
| NTRA | SN | |
|---|---|---|
Market Cap | $57.03B | $26.25B |
Volume | 1,131,157 | 1,135,281 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $192.86 |
52-Week Low | $179.42 | $84.57 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $56.18B | $26.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SharkNinja (SN) trades at $188.80, down 0.62% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, 10.06% net margin, and robust cash flow growth. Recent product launches including new vacuum and kitchen systems highlight ongoing innovation. Analyst sentiment remains overwhelmingly positive with 91% buy ratings and a $202.18 consensus target.
SN presents a compelling growth story with strong profitability and product momentum, though elevated P/E of 38.5 suggests premium valuation. Key risks include consumer spending sensitivity and competitive pressures in home appliances. The stock's proximity to resistance at $192 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About SharkNinja Inc. Ordinary Shares
SharkNinja designs and sells small household appliances under the Shark and Ninja brands. Its products include cleaning appliances, kitchen and beverage appliances, food preparation products, and beauty and home-environment devices.
Read more on SN →
